Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05778864 · ClinicalTrials.gov registry record · Phase 1
A Study of LY3473329 in Participants With Impaired and Normal Renal Function
A Phase 1 study of Renal Insufficiency, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 4
- Study locations
NCT05778864: Completed Phase 1 study of Renal Insufficiency, sponsored by Eli Lilly and Company.
NCT05778864 is a Phase 1 study of Renal Insufficiency that has completed, run by Eli Lilly and Company. The registered enrollment target is 47 participants, below the 99-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (53% lower). The trial reports 4 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05778864, a Phase 1 study of Renal Insufficiency, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 4
- Study locations
Study Summary
The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability of LY3473329 will also be evaluated in these participants. The study will last up to 8 weeks including screening period.
Primary Outcome
PK: AUC0-∞ of LY3473329
Conditions Studied
Interventions
- DRUG LY3473329
Study Locations (4)
Florida
- Velocity Clinical Research, New Smyrna Beach - Edgewater
- Advanced Pharma CR, LLC - Miami
- Orlando Clinical Research Center - Orlando
Tennessee
- Alliance for Multispecialty Research, LLC - Knoxville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2023-03-17 |
| Est. Completion | 2024-09-06 |
| Phase | Phase 1 |
What the finished NCT05778864 record still lists
NCT05778864 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 99-participant average among 22 other Renal Insufficiency trials with a reported enrollment target (53% lower).
The record links to 1 condition, with Renal Insufficiency appearing as the primary indexed condition, and to 1 intervention - of which LY3473329 is the first listed.
NCT05778864 reports a single indexed study location in Florida, Tennessee.
Frequently Asked Questions
What is clinical trial NCT05778864 about?
NCT05778864 is a clinical study titled "A Study of LY3473329 in Participants With Impaired and Normal Renal Function". The main purpose of this study is to assess the amount of study drug (LY3473329) that reaches the bloodstream and the time it takes for the body to get rid of it when given to participants with renal (kidney) impairment compared to participants with normal renal function. The safety and tolerability...
What is the current status of trial NCT05778864?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2023-03-17. Estimated completion is 2024-09-06.
What conditions does trial NCT05778864 study?
This clinical trial studies the following conditions: Renal Insufficiency.
What interventions are being tested in trial NCT05778864?
The interventions under investigation include: LY3473329 (DRUG).
Who is sponsoring clinical trial NCT05778864?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05778864 being conducted?
This trial has 4 study locations across Florida, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Insufficiency
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05778864's enrollment target sits among peer trials
47 7th of 22 higher than 16 of 22 other Renal Insufficiency trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Renal Insufficiency trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of LY3537982 in Participants With Kidney Problems Compared With Participants With Normal Kidney Function
RECRUITING · Phase 1
-
A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function
RECRUITING · Phase 1
-
A Study of Pharmacokinetics and Safety of LY3537031 in Participants With Normal Renal Function and Participants With Renal Impairment
ACTIVE NOT RECRUITING · Phase 1
-
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
COMPLETED · Phase 1
-
"Pharmacokinetic Study of Fondaparinux in Inpatients With Renal Dysfunction"
COMPLETED · Phase 1
-
Pharmacokinetics and Safety of Fevipiprant in Patients With Renal Impairment Compared to Matched Healthy Subjects
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI